Dalteparin sodium injection_Dalteparin sodium injection_Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Dalteparin sodium injection
en.hbcsbio.comCrawled Nov 3, 2026
Dalteparin sodium injection
Enoxaparin sodium injection
Nadroparin calcium injection
Changshan Pharmacy, invested by the company, earned GSP certification in 2015 and operates a 208.38-square-meter facility in Shijiazhuang City. It offers traditional Chinese patent medicines, western medicines, medical equipment, and healthcare products.
In 2014, the Hebei provincial government approved Hebei Changshan Biochemical Pharmaceutical Co., Ltd. to establish non-profit hemodialysis centers in six cities: Shijiazhuang, Hengshui, Zhangzhou, Langfang, Tangshan, and Qinhuangdao.
Business Scope: Investing in hospitals and independent blood purification centers with its own funds, and managing the projects it has invested in. (Projects to be approved by law may be operated once the approval of relevant authorities has been gained).
Business Scope: research and development, production and sales of polysaccharide and polypeptide products, development and consultation of chemical synthesis technology.
Business Scope: research and development of biological products and technology; research, development, production and sales of hyaluronic acid raw materials and series products.
Hebei Changshan Kalal Biotech Co., Ltd. (Kaila Biotech) is a subsidiary of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (Changshan Pharmaceutical) focused on developing halal drugs for international markets.
The company is a key high-tech enterprise with products from heparin crude products to low molecular weight heparin injections and a complete heparin industrial chain in the field of heparin, and a leading pharmaceutical company in the production of domestic heparin products.
The company is a key high-tech enterprise with products from heparin crude products to low molecular weight heparin injections and a complete heparin industrial chain in the field of heparin, and a leading pharmaceutical company in the production of domestic heparin products.
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. reports **CNY 736.37 million in sales and revenue** for the nine months ending September 30, 2026. This marks an increase from **CNY 681.22 million** reported in the same period the prior year. The company’s financial performance reflects growth in its pharmaceutical operations over the latest quarterly period.
Hebei Changshan Biochemical Pharmaceutical secures EU approval for its enoxaparin sodium injection through a decentralized review process, with Croatia serving as the lead member state. The drug, an anticoagulant, now meets regulatory requirements for distribution within the European Union. The company’s product advances its position in the global pharmaceutical market.
Hebei Changshan Biochemical Pharmaceutical secures regulatory approval in Moldova for its heparin sodium injection, an anticoagulant drug. The registration follows a filing submitted to Shenzhen’s regulatory authorities. This marks the company’s expansion into the Moldovan pharmaceutical market.
Hebei Changshan Biochemical Pharmaceutical secures US FDA approval for its generic enoxaparin sodium injection, an anticoagulant drug. The filing confirms the company’s ability to manufacture and distribute the medication in the US market. This approval expands Changshan’s presence in the global pharmaceutical industry.
Hebei Changshan Biochemical Pharmaceutical Co. Ltd. (XSEC: 300255) has been included in the FTSE All-World Index. The company, listed on the Xetra exchange, gains broader global market exposure through this addition.
Hebei Changshan Biochemical Pharmaceutical is a China-based heparin-focused drugmaker producing crude heparin, active ingredients, and low molecular weight heparin injections.